Department of Genetics, UCL Institute of Ophthalmology, University College London, London, United Kingdom.
Exp Eye Res. 2012 Feb;95(1):54-9. doi: 10.1016/j.exer.2011.07.001. Epub 2011 Jul 18.
Transfer of cDNA to corneal endothelial cells has been demonstrated in cell monolayers in vitro, in endothelium of whole thickness corneas ex vivo and following intracameral injection. Studies examining the feasibility and optimal methods for gene transfer to the cornea have used viral and non-viral vectors, initially histochemical or fluorescent marker genes, and in endothelium of numerous species ranging from mouse to man. As the feasibility of genetic modification of corneal endothelial cells has been successfully demonstrated in a number of cell culture and animal models, there is significant potential for gene transfer in the treatment of human corneal endothelial disease. The two most widely studied applications of gene transfer to endothelium are (i) transduction of immunomodulatory genes to donor corneal endothelium prior to transplantation as a strategy to delay allogeneic rejection and (ii) modulation of apoptosis or induction of replication in human corneal endothelial cells to increase cell density. Although continued improvements in vectors for gene transfer will improve the efficacy and safety of gene therapy, more detailed understanding of the altered biology of endothelium in disease will be necessary to allow selection of appropriate targets for a gene-based treatment approach.
已在体外细胞单层、活体全厚角膜内皮以及房内注射后证明 cDNA 可转移至角膜内皮细胞。研究基因转移到角膜的可行性和最佳方法的实验使用了病毒和非病毒载体,最初是组织化学或荧光标记基因,并在从鼠到人等多种物种的内皮中进行。由于已在一些细胞培养和动物模型中成功证明了对角膜内皮细胞进行遗传修饰的可行性,因此在治疗人类角膜内皮疾病方面,基因转移具有很大的潜力。基因转移到内皮的两个最广泛研究的应用是:(i) 在移植前将免疫调节基因转导到供体角膜内皮,作为延迟同种异体排斥反应的策略;(ii) 调节人角膜内皮细胞的细胞凋亡或诱导其复制,以增加细胞密度。尽管用于基因转移的载体的不断改进将提高基因治疗的疗效和安全性,但需要更详细地了解疾病中内皮细胞的改变生物学特性,以便为基于基因的治疗方法选择适当的靶点。